Self-Assembling Peptide Nanoparticle Vaccine Platform
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine technologies face challenges in efficiently inducing broad humoral immunity and CD8+ T-cell responses, particularly for HIV and influenza, due to difficulties in nanoparticle synthesis, purification, and stability, as well as limitations in protein vaccines' delivery and storage.
Innovation Solution
The development of nucleic acid sequences encoding self-assembling nanoparticles and peptide antigens, which are administered using advanced synthetic electroporation technology to bypass in vitro assembly and purification steps, enabling rapid and robust immune responses without relying on opsonization by the innate immune system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nanoparticle vaccines are synthesized and purified using conventional methods, then antigen presentation is improved, but manufacturing complexity and time increase
Solution Approach 1:
The patent employs self-assembling peptide nanoparticles that automatically form ordered structures in vivo without requiring external assembly assistance. The peptides contain amphipathic helices that spontaneously organize into nanoscale particles upon administration, eliminating the need for complex in vitro assembly and purification processes while maintaining reliable antigen presentation.
Solution Approach 2:
The vaccine design pre-organizes the antigen presentation structure at the molecular level through carefully engineered peptide sequences that contain built-in self-assembly domains. This preliminary structural organization ensures that upon administration, the nanoparticles automatically form the desired immunogenic structures without requiring post-administration manipulation or complex manufacturing steps.
2Reliability
If protein vaccines are administered, then immune response is induced, but storage stability deteriorates
Solution Approach 1:
The patent transitions from protein-based vaccines to peptide-based vaccines, fundamentally changing the molecular parameters of the immunogen. The small peptide sequences are inherently more stable than full-length proteins, resisting denaturation and degradation during storage while still capable of inducing robust immune responses when presented in the self-assembled nanoparticle format.
3Quantity of substance
If conventional vaccine delivery is used, then antigen exposure occurs, but delivery efficiency decreases
Solution Approach 1:
The patent replaces complex mechanical delivery systems with a simplified approach where the vaccine antigen itself provides the delivery mechanism. The self-assembling peptide nanoparticles are small enough to naturally penetrate tissue and present antigen to immune cells without requiring sophisticated delivery devices, electroporation, or other mechanical assistance, thereby improving delivery efficiency while ensuring adequate antigen exposure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in potent and durable humoral and cellular immune responses, including stronger CD8+ T-cell responses, facilitating the rapid translation of vaccine candidates into clinical use and improving the efficacy of vaccines against various viral infections.
Implementation Method 1
administered using advanced synthetic electroporation technology
Implementation Method 2
nucleic acid sequences encoding self-assembling nanoparticles and peptide antigens
Data Source
AI summary
Disclosed are compositions comprising an expressible nucleic acid sequence comprising a first nucleic acid sequence comprising a leader sequence or a pharmaceutically acceptable salt thereof; and a second nucleic acid sequence comprising a sequence that encodes a self-assembling polypeptide or a pharmaceutically acceptable salt thereof. In some embodiments, the expressible nucleic acid sequence further comprises a nucleic acid sequence encoding at least one viral antigen or a pharmaceutically acceptable salt thereof. In some embodiments, the expressible nucleic acid sequence further comprises at least one nucleic acid sequence encoding a linker. Also disclosed are pharmaceutical compositions comprising these compositions and methods of using the disclosed compositions.